Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic

A Phase 2 Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy of Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic

The goal of this study is to test the efficacy of Dupixent in improving post-burn itching symptoms versus the current standard of care.

Study Overview

• Status: Recruiting
• Conditions: Pruritis
• Intervention / Treatment: Drug: Dupilumab; Other: Placebo

Detailed Description

Participants will receive six injections of Dupixent or placebo (two 300 mg loading doses and one 300 mg dose every two weeks after that).

In addition, participants will be asked to complete questionnaires to determine daily itch severity, quality of life, treatment benefit, physical functioning, and pain interference.

Individual participants will require 13 weeks to complete all study visits.

• Study Type: Interventional
• Enrollment (Estimated): 46
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Anjay Khandelwal, MD; Phone Number: 330-543-4649; Email: akhandelwal@akronchildrens.org
• Study Contact Backup: Name: Jessica Kracker, BSN; Phone Number: 330-543-0846; Email: jkracker@akronchildrens.org

Study Locations

• United States
  • Ohio
    • Akron, Ohio, United States, 44308
      • Recruiting
      • Akron Children's Hospital
      • Contact: Anjay Khandelwal, MD; Phone Number: 330-543-4649; Email: akhandelwal@akronchildrens.org
      • Principal Investigator: Anjay Khandelwal, MD
      • Sub-Investigator: Richard Lou, MD
      • Contact: Jessica Kracker, BSN; Phone Number: 330-543-0846; Email: jkracker@akronchildrens.org

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Persons 18-60 year old with post-burn hypertrophic scars of any size which required grafting or epidermal autografting for an acute burn injury, with continued complaint of pruritus due to inadequate relief from standard of care (medical management by antihistamine and neuroleptic medications) after at least four weeks and are a minimum of four weeks after their last grafting surgery, and who speak English sufficient to participate in the study.

Exclusion Criteria:

• Currently taking Dupixent for any other diagnosis
• known allergy to Dupixent
• pregnant and or lactating mothers
• anyone treated for pruritus using laser therapy
• currently receiving adequate relief for pruritis under standard of care medical management by antihistamine or neuroleptic medications
• Currently taking steroids
• persons with developmental delays or otherwise unable to complete measures
• prisoners or anyone otherwise unable to give their own consent or who is not their own guardian
• one or more of the following existing disorders: conjunctivitis; any co-existing dermatological condition except burns; any type of cancer; requiring dialysis; chronic Stage 3 or higher kidney disease; biliary disorder; gall bladder disorder; or another renal or hepatic disorder which, in the opinion of study physician, deems this study inappropriate for an eligible individual.
• Persons unable to provide their own consent, including prisoners when their incarcerated status is not itself the focus of study, are routinely excluded from clinical trials at this site
• We further exclude persons with other dermatological conditions (other than burn) , which may have pruritis or pain associated with them and who may be treated with medications other than Dupixent, and whose perceived benefit could confound our results.
• We similarly exclude anyone treated for pruritis by laser therapy as their perceived benefit could confound our results.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: ARM 1 - Dupixent; Two subcutaneous injection of 300mg Dupixent at visit 1 and every two weeks (+/- 2 days) for a total of 6 administrations. Injections may be administered in the thigh, lower abdomen or upper arm. The initial dose (two 300 mg doses) will be given in two different injection sites. There are not restriction or guidance regarding dose administration related to meals. No dose modifications will occur during study participation.	Drug: Dupilumab; injection every two weeks while on study
Placebo Comparator: ARM 2 - Placebo; Two subcutaneous injection of the placebo at visit 1 and every two weeks (+/- 2 days) for a total of 6 administrations. Injections may be administered in the thigh, lower abdomen or upper arm. The initial dose (two doses) will be given in two different injection sites. There are not restriction or guidance regarding dose administration related to meals. No dose modifications will occur during study participation.	Other: Placebo; injection every two weeks while on study

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Itch Severity Scale (ISS) Scores	Participants' Itch Severity Scale (ISS) scores will decrease more than 2.0 points after 12 weeks following initiating use of Dupixent	12 WEEKS

Collaborators and Investigators

• Sponsor: Akron Children's Hospital
• Collaborators: Regeneron Pharmaceuticals; Ohio State University

Study record dates

Study Major Dates

• Study Start (Actual): November 21, 2024
• Primary Completion (Estimated): January 31, 2026
• Study Completion (Estimated): December 31, 2026

Study Registration Dates

• First Submitted: January 18, 2024
• First Submitted That Met QC Criteria: January 18, 2024
• First Posted (Actual): January 26, 2024

Study Record Updates

• Last Update Posted (Estimated): September 19, 2025
• Last Update Submitted That Met QC Criteria: September 16, 2025
• Last Verified: December 1, 2024

More Information

Terms related to this study

• Keywords: Itching, itch
• Additional Relevant MeSH Terms: Skin Manifestations; Skin Diseases; Pathological Conditions, Signs and Symptoms; Skin and Connective Tissue Diseases; Signs and Symptoms; Pruritus; Substandard Drugs; Pharmaceutical Preparations; dupilumab
• Other Study ID Numbers: 2024-002

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes